^
    Contact us  to learn more about
    our Premium Content:  News alerts, weekly reports and conference planners
    DRUG:

    tegavivint (BC2059)

    i
    Other names: BC2059, BC 2059, BC-2059, NSC#826393, APL-121
    Company:
    Apollomics, Iterion Therap
    Drug class:
    β-catenin inhibitor, Wnt signalling pathway inhibitor
    Related drugs:
    11d
    Tegavivint for the Treatment of Relapsed or Refractory Leukemia (clinicaltrials.gov)
    P1, N=9, Active, not recruiting, M.D. Anderson Cancer Center | Trial completion date: Dec 2025 --> Feb 2027 | Trial primary completion date: Dec 2025 --> Feb 2027
    Trial completion date • Trial primary completion date
    |
    decitabine • tegavivint (BC2059)
    30d
    Tegavivint With Gemcitabine in Patients With Relapsed or Refractory Osteosarcoma (clinicaltrials.gov)
    P1, N=24, Not yet recruiting, Emory University | Initiation date: Oct 2025 --> Jan 2026
    Trial initiation date
    |
    gemcitabine • tegavivint (BC2059)
    1m
    OSU-20298: Osimertinib and Tegavivint as First-Line Therapy for the Treatment of Metastatic EGFR-Mutant Non-small Cell Lung Cancer (clinicaltrials.gov)
    P1, N=24, Recruiting, Ohio State University Comprehensive Cancer Center | Trial primary completion date: Jul 2025 --> Jul 2026
    Trial primary completion date
    |
    EGFR mutation • EGFR L858R • EGFR exon 19 deletion • EGFR T790M • EGFR L861Q • EGFR G719X • EGFR S768I
    |
    Tagrisso (osimertinib) • tegavivint (BC2059)
    5ms
    Tegavivint With Gemcitabine in Patients With Relapsed or Refractory Osteosarcoma (clinicaltrials.gov)
    P1, N=24, Not yet recruiting, Emory University
    New P1 trial
    |
    gemcitabine • tegavivint (BC2059)
    9ms
    A Study of Tegavivint (BC2059) in Patients With Advanced Hepatocellular Carcinoma (clinicaltrials.gov)
    P1/2, N=178, Recruiting, Iterion Therapeutics | N=108 --> 178
    Enrollment change
    |
    AXIN1 (Axin 1)
    |
    Lenvima (lenvatinib) • Cabometyx (cabozantinib tablet) • tegavivint (BC2059)
    11ms
    Targeting the DNA Damage Response through TBL1X in Mantle Cell Lymphoma. (PubMed, Blood Adv)
    Combining tegavivint with PARP-1/2 inhibitor talazoparib results in synergistic MCL cell death in vitro, and in vivo this combination significantly prolonging the survival of an MCL PDX. Together, our results define the role of TBL1X in maintaining genomic stability in MCL and establish targeting TBL1X as a novel therapeutic strategy for patients with this incurable disease.
    Journal • PARP Biomarker
    |
    CCND1 (Cyclin D1) • RAD51 (RAD51 Homolog A)
    |
    Talzenna (talazoparib) • tegavivint (BC2059)
    12ms
    Tegavivint for the Treatment of Relapsed or Refractory Leukemia (clinicaltrials.gov)
    P1, N=9, Active, not recruiting, M.D. Anderson Cancer Center | Trial completion date: Dec 2024 --> Dec 2025 | Trial primary completion date: Dec 2024 --> Dec 2025
    Trial completion date • Trial primary completion date
    |
    decitabine • tegavivint (BC2059)
    1year
    Osimertinib and Tegavivint As First-Line Therapy for the Treatment of Metastatic EGFR-Mutant Non-small Cell Lung Cancer (clinicaltrials.gov)
    P1, N=24, Recruiting, Ohio State University Comprehensive Cancer Center | N=18 --> 24 | Trial completion date: Dec 2024 --> Jul 2029 | Trial primary completion date: Dec 2024 --> Jul 2025
    Enrollment change • Trial completion date • Trial primary completion date
    |
    EGFR (Epidermal growth factor receptor) • NOTCH3 (Notch Receptor 3)
    |
    EGFR mutation • EGFR L858R • EGFR exon 19 deletion • EGFR T790M • EGFR L861Q • EGFR G719X • EGFR S768I
    |
    Tagrisso (osimertinib) • tegavivint (BC2059)
    1year
    Osimertinib and Tegavivint As First-Line Therapy for the Treatment of Metastatic EGFR-Mutant Non-small Cell Lung Cancer (clinicaltrials.gov)
    P1, N=24, Recruiting, Ohio State University Comprehensive Cancer Center | N=18 --> 24 | Trial completion date: Dec 2024 --> Jul 2029 | Trial primary completion date: Dec 2024 --> Jul 2025
    Enrollment change • Trial completion date • Trial primary completion date
    |
    EGFR (Epidermal growth factor receptor) • NOTCH3 (Notch Receptor 3)
    |
    EGFR mutation • EGFR L858R • EGFR exon 19 deletion • EGFR T790M • EGFR L861Q • EGFR G719X • EGFR S768I
    |
    Tagrisso (osimertinib) • tegavivint (BC2059)
    almost2years
    Cytosolic Cadherin 4 promotes angiogenesis and metastasis in papillary thyroid cancer by suppressing the ubiquitination/degradation of β-catenin. (PubMed, J Transl Med)
    CDH4 induces PTC angiogenesis and metastasis via the inhibition of β-TrCP1-dependent ubiquitination of β-Catenin.
    Journal
    |
    CTNNB1 (Catenin (cadherin-associated protein), beta 1)
    |
    tegavivint (BC2059)
    almost2years
    Tegavivint for the Treatment of Relapsed or Refractory Leukemia (clinicaltrials.gov)
    P1, N=9, Active, not recruiting, M.D. Anderson Cancer Center | Recruiting --> Active, not recruiting | N=54 --> 9 | Trial completion date: Dec 2023 --> Dec 2024 | Trial primary completion date: Dec 2023 --> Dec 2024
    Enrollment closed • Enrollment change • Trial completion date • Trial primary completion date
    |
    decitabine • tegavivint (BC2059)
    2years
    Osimertinib and Tegavivint as First-Line Therapy for the Treatment of Metastatic EGFR-Mutant Non-small Cell Lung Cancer (clinicaltrials.gov)
    P1, N=18, Recruiting, Ohio State University Comprehensive Cancer Center | Trial primary completion date: Dec 2023 --> Dec 2024
    Trial primary completion date • Metastases
    |
    EGFR (Epidermal growth factor receptor) • NOTCH3 (Notch Receptor 3)
    |
    EGFR mutation • EGFR L858R • EGFR exon 19 deletion • EGFR T790M • EGFR L861Q • EGFR G719X • EGFR S768I
    |
    Tagrisso (osimertinib) • tegavivint (BC2059)